IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.
IPO Year: 2021
Exchange: NASDAQ
Website: iobiotech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/30/2021 | $21.00 | Overweight | Morgan Stanley |
| 11/30/2021 | Outperform | Cowen & Co. | |
| 11/30/2021 | $20.00 | Buy | Jefferies |
EFFECT - IO Biotech, Inc. (0001865494) (Filer)
8-K - IO Biotech, Inc. (0001865494) (Filer)
8-K - IO Biotech, Inc. (0001865494) (Filer)
S-3 - IO Biotech, Inc. (0001865494) (Filer)
10-Q - IO Biotech, Inc. (0001865494) (Filer)
8-K - IO Biotech, Inc. (0001865494) (Filer)
8-K - IO Biotech, Inc. (0001865494) (Filer)
DEFA14A - IO Biotech, Inc. (0001865494) (Filer)
DEF 14A - IO Biotech, Inc. (0001865494) (Filer)
S-8 - IO Biotech, Inc. (0001865494) (Filer)